on Facebookon Twitter on YoutubeRSS

Niacin Research and Studies

  1. ^ “Niacin – PubChem Public Chemical Database”. The PubChem Project. USA: National Center for Biotechnology Information.
  2. ^ Jaconello P (October 1992). “Niacin versus niacinamide”. CMAJ147 (7): 990. PMC 1336277PMID 1393911.
  3. ^ Knip M, Douek IF, Moore WP, et al. (2000). “Safety of high-dose nicotinamide: a review”. Diabetologia 43 (11): 1337–45.doi:10.1007/s001250051536PMID 11126400.
  4. ^ Cox, Michael; Lehninger, Albert L; Nelson, David R. (2000).Lehninger principles of biochemistry. New York: Worth Publishers.ISBN 1-57259-153-6.
  5. ^ [1] NIH stops clinical trial on combination cholesterol treatment
  6. ^ United States Department of Agriculture, National Agriculture Library, Food and Nutrition Information Center, Dietary Reference Intakes: Recommended Intakes for Individuals, Vitamins [2]
  7. ^ Institute of Medicine. (2006). Dietary Reference Intakes Research Synthesis: Workshop Summary, p. 37. National Academies Press.
  8. ^ Jacob RA, Swendseid ME, McKee RW, Fu CS, Clemens RA (April 1989). “Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites”. J. Nutr.119 (4): 591–8. PMID 2522982.
  9. ^ Pitsavas, Stergios; Christina Andreou, Franzesca Bascialla, Vasilis P. Bozikas, Athanasios Karavatos (2004). “Pellagra Encephalopathy Following B-Complex Vitamin Treatment without Niacin”.International Journal of Psychiatry in Medicine 31 (1): 91–96. Retrieved 2009-11-27.
  10. a b c d Prakash, Ravi; Sachin Gandotra, Lokesh Kumar Singh, Basudeb Das, Anuja Lakra (2008). “Rapid resolution of delusional parasitosis in pellagra with niacin augmentation therapy”. General Hospital Psychiatry 30 (6): 581–4.doi:10.1016/j.genhosppsych.2008.04.011PMID19061687.
  11. a b Katzung, Bertram G. (2006). Basic and clinical pharmacology. New York: McGraw-Hill Medical Publishing Division.ISBN 0071451536.
  12. ^ McGovern ME (2005). “Taking aim at HDL-C. Raising levels to reduce cardiovascular risk”. Postgrad Med 117 (4): 29–30, 33–5, 39 passim.PMID 15842130.
  13. ^ Canner PL, Berge KG, Wenger NK, et al. (1986). “Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin”. J. Am. Coll. Cardiol. 8 (6): 1245–55. doi:10.1016/S0735-1097(86)80293-5PMID 3782631.
  14. ^ N Engl J Med 361:2113
  15. ^ Singer, Natasha (November 15, 2009). “Study Raises Questions About Cholesterol Drug’s Benefit”The New York Times. Retrieved November 16, 2009.
  16. ^ Bruckert, E; Labreuche, J; Amarenco, P (2010). “Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis”. Atherosclerosis 210 (2): 353–61.doi:10.1016/j.atherosclerosis.2009.12.023PMID 20079494.
  17. ^ http://www.npr.org/blogs/health/2011/05/28/136678665/study-boosting-good-cholesterol-with-niacin-did-not-cut-heart-risks?ps=sh_sthdl
  18. a b c d Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). Goodman & Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill.ISBN 0071422803.
  19. ^ “Guidelines for Niacin Therapy For the Treatment of Elevated Lipoprotein a (Lpa)”Rush Hemophilia & Thrombophilia Center. August 15, 2002, Revised July 27, 2005. Retrieved 20 November 2009. “facial flushing is a common side effect of niacin therapy that usually subsides after several weeks of consistent niacin use”
  20. ^ Barter, P (2006). “Options for therapeutic intervention: How effective are the different agents?”. European Heart Journal Supplements 8(F): F47–F53. doi:10.1093/eurheartj/sul041.
  21. ^ Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004). “Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid–a position paper developed by the European Consensus Panel on HDL-C”. Curr Med Res Opin 20 (8): 1253–68. doi:10.1185/030079904125004402.PMID 15324528.
  22. a b Papaliodis D, Boucher W, Kempuraj D, Michaelian M, Wolfberg A, House M, Theoharides TC (December 2008). “Niacin-induced “Flush” Involves Release of Prostaglandin D2 from Mast Cells and Serotonin from Platelets: Evidence from Human Cells in Vitro and an Animal Model”. J Pharmacol Exp Ther 327 (3): 665–72.doi:10.1124/jpet.108.141333PMID 18784348.
  23. ^ Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM (2000). “Niacin dosing: relationship to benefits and adverse effects”. Curr Atheroscler Rep 2 (1): 64–71. doi:10.1007/s11883-000-0096-y.PMID 11122726.
  24. ^ Mittal MK, Florin T, Perrone J, Delgado JH, Osterhoudt KC (2007). “Toxicity from the use of niacin to beat urine drug screening”. Ann Emerg Med 50 (5): 587–90.doi:10.1016/j.annemergmed.2007.01.014PMID 17418450.
  25. ^ Gass JD (2003). “Nicotinic acid maculopathy. 1973″. Retina (Philadelphia, Pa.) 23 (6 Suppl): 500–10. PMID 15035390.
  26. ^ Taheri, R (2003-01-15). “No-Flush Niacin for the Treatment of Hyperlipidemia”Medscape. Retrieved 2008-03-31.
  27. ^ Kruse W, Kruse W, Raetzer H, Heuck CC, Oster P, Schellenberg B, Schlierf G (1979). “Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives”. European Journal of Clinical Pharmacology 16(1): 11–15. doi:10.1007/BF00644960PMID 499296.
  28. ^ Meyers CD, Carr MC, Park S, Brunzell JD (2003). “Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia”. Annals of Internal Medicine 139 (12): 996–1002.PMID 14678919.
  29. ^ Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS, Brandizzi LI, da Luz PL (2006). “Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment”. Atherosclerosis 187 (1): 116–122.doi:10.1016/j.atherosclerosis.2005.08.025PMID 16458316.
  30. ^ Jacobson, EL (2007). “Niacin”Linus Pauling Institute. Retrieved 2008-03-31.
  31. ^ Zhang Y, Schmidt RJ, Foxworthy P, et al. (2005). “Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A”. Biochem. Biophys. Res. Commun. 334 (2): 729–32.doi:10.1016/j.bbrc.2005.06.141PMID 16018973.
  32. ^ Zellner C, Pullinger CR, Aouizerat BE, et al. (2005). “Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors”.Hum. Mutat. 25 (1): 18–21. doi:10.1002/humu.20121.PMID 15580557.
  33. ^ Weidel, H (1873). “Zur Kenntniss des Nicotins”. Justus Liebig’s Annalen der Chemie und Pharmacie 165 (2): 330–349.doi:10.1002/jlac.18731650212.
  34. ^ Samuel M. McElvain (1941), “Nicotinic Acid”Org. Synth.; Coll. Vol. 1: 385
  35. ^ Elvehjem, C.A.; Madden, R.J.; Strongandd, F.M.. “W. WOOLLEY 1938 The isolation and identification of the anti-blacktongue factor J”.J. Biol. Chem 123: 137.
  36. ^ LAGUNA J, CARPENTER KJ (September 1951). “Raw versus processed corn in niacin-deficient diets”. J. Nutr. 45 (1): 21–8.PMID 14880960.
  37. ^ “Vitamin B3″University of Maryland Medical Center. 2002-01-04. Retrieved 2008-03-31.
  38. ^ Paolini JF, Bays HE, Ballantyne CM, et al. (November 2008). “Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors”. Cardiol Clin 26 (4): 547–60.doi:10.1016/j.ccl.2008.06.007.PMID 19031552.

Vitamin B3 Niacin Supplements